1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Co., Ltd.

TTPEX:4130
26.70
TWD
-0.10
(-0.37%)
-0.07EPS
4.44BMarket Cap
Genovate Biotechnology Co., Ltd.
TPEX:4130
(Taipei Exchange)

Recent

price

26.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
2.99
3.27
3.03
3.46
4.14
4.01
3.44
3.44
3.84
3.92
4.04
3.71
3.75
4.45
4.32
4.19
3.73
Revenue per Share
0.36
0.55
0.53
0.4
0.63
0.39
0.33
1.25
0.49
0.29
0.33
- -
-0.11
0.25
0.22
0.1
-0.07
Basic EPS, GAAP
-0.03
0.48
0.12
0.76
0.42
-0.2
0.25
-0.06
0.22
0.13
0.51
-0.3
-0.19
0.43
0.2
-0.15
-0.32
Free Cash Flow per Basic Share
- -
- -
- -
0.25
0.25
0.42
0.42
0.3
0.68
0.25
0.41
0.37
0.32
0.16
0.14
0.09
- -
Dividend per Share
6.57
7.01
8.77
8.87
10.44
17.83
18.83
13.48
13.17
12.03
12.19
11.78
11.89
12.38
12.34
11.75
14.57
Book Value per Share
6.57
6.92
8.68
8.82
10.41
17.79
18.8
13.46
13.15
12
12.16
11.77
11.88
12.34
12.31
11.7
14.53
Tangible Book Value per Share
101
101
115
115
115
119
119
119
119
119
117
117
117
119
118
117
126
Basic Weighted Avg Shares
302
331
348
397
475
478
411
408
456
466
473
434
439
529
511
492
471
Sales/Revenue/Turnover
1.69
8.97
4.28
9.96
15.97
11.81
3.91
0.18
6.94
8.48
8.35
-0.27
-3.17
5.11
4.59
1.4
-3.65
Operating Margin (%)
24
25
23
25
23
26
30
31
32
34
35
36
36
37
38
39
38
Depreciation Expense
36
56
61
46
73
46
39
149
58
34
39
- -
-12
29
26
12
-9
Net Income, GAAP
9.52
8.86
8.02
12
11.21
20.04
9.37
6.78
9.52
16.27
4.97
89.57
- -
4.84
17.26
13.17
- -
Effective Tax Rate (%)
11.98
16.79
17.42
11.5
15.26
9.73
9.54
36.49
12.69
7.31
8.19
0.09
-2.81
5.55
5.03
2.37
-1.94
Profit Margin (%)
363
453
662
582
724
861
560
608
549
553
515
524
650
654
629
594
1,240
Working Capital
- -
- -
- -
- -
231
237
- -
- -
- -
- -
1
- -
1
- -
2
1
- -
LT Debt
759
810
1,013
1,024
1,199
2,124
2,249
1,600
1,563
1,408
1,426
1,379
1,411
1,469
1,449
1,380
1,992
Total Equity
0.62
3.43
1.5
3.4
5.47
2.37
0.6
0.03
1.79
2.21
2.62
-0.01
- -
1.78
1.32
0.42
- -
Return on Invested Capital (%)
4.85
7.09
6.65
4.48
5.91
2.71
1.85
7.57
3.65
2.3
2.73
0.03
- -
2.05
1.79
0.87
- -
Return on Capital (%)
4.89
7.09
6.66
4.48
6.53
2.8
1.79
7.74
3.66
2.29
2.73
0.03
-0.88
2.04
1.76
0.83
-0.54
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
117
117
137
Market Capitalization
2,622
3,151
4,444

Working Capital

TWD

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
716
719
1,346
Cash, Cash Equivalents & STI
466
482
1,111
Accounts Receivable, Net
75
74
67
Inventories
151
144
139
Total Current Liabilities
120
125
106
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.69%
-0.59%
-4.75%
Free Cash Flow
-131.75%
-150.43%
-174.25%
Net Income, GAAP
-374.1%
-783.33%
-54.54%
Sales/Revenue/Turnover
0.71%
1.28%
-3.61%
Total Cash Common Dividend
- -
-23.72%
-32.02%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
139
127
126
118
511
2025
131
126
116
119
492
2026
110
- -
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.07
0.05
-0.04
0.22
2025
0.08
0.07
-0.01
-0.03
0.1
2026
-0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.14
2025
- -
- -
- -
- -
0.09
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Genovate Biotechnology Co., Ltd. (4130.TWO) engages in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates, with a focus on specialty drugs for the Taiwanese market; its core products encompass nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs including Livepro (entecavir), cardiovascular system drugs such as cilostazol formulations, acne drugs, antineoplastic drugs like Genetaxyl (paclitaxel injection), anti-diabetic drugs including DBPR108, healthcare foods and cosmetics; the company also provides clinical experimental testing services (CRO/GCP), technology export services and contract manufacturing compliant with PIC/S GMP and PMDA standards for sterile preparations. Founded in 1993 and headquartered at No. 1, First Industrial Road, Hukou Township, Hsinchu County, Taiwan, Genovate operates primarily in Taiwan with exports and partnerships extending to China, Japan, the US, Australia, Europe and New Zealand, employing approximately 191-195 staff and listing on the Taipei Exchange (TPEx) since 2012. Recent developments include plans announced in May 2024 to submit a New Drug Application (NDA) for PMR (cilostazol extended-release tablets) to the US FDA under the 505(b)(2) pathway in the second half of 2025 for intermittent claudication; in 2023, partner CSPC Pharmaceutical Group filed and had accepted an NDA for DBPR108 (DPP-4 inhibitor) with China's NMPA following Phase III trials; Synmosa Biopharma proposed acquiring a 30% stake for TWD 830 million; GVX171/GX17 (S-(+)-hydroxychloroquine enantiomer) received US FDA approval in 2022 for first-in-human trials targeting antiphospholipid syndrome; ongoing investments and joint ventures persist with NaviFUS for neuronavigation-guided focused ultrasound systems in CNS diseases via subsidiaries like Genovate NaviFUS (Australia), UniPharma for GX17, and historical ties to CSPC (2012 onward) and Otsuka for PMR in Asia-Pacific.